Editorial Comment on Bayesian Reanalysis of Enzalutamide Plus Androgen Deprivation Therapy in Japanese Patients With Metastatic Hormone‐Sensitive Prostate Cancer: A Methodological Complement to Frequentist Analysis From the <scp>ARCHES</scp> Trial

The ARCHES trial and its Japanese subgroup analysis provide an instructive case study for examining how statistical interpretation influences perceived evidence strength in global oncology trials. Yajima et al. present an elegant Bayesian reanalysis of the Japanese cohort from ARCHES, reframing a statistically non-significant hazard ratio (HR 0.39, 95% CI 0.13–1.18) through probabilistic reasoning [1]. Their work underscores an increasingly relevant methodological issue: how should investigators interpret subgroup findings when limited sample size, not lack of efficacy, drives uncertainty? Frequentist inference, while familiar and widely adopted, offers only a dichotomous lens—“significant” or “not significant”—based on whether the confidence interval crosses unity. Yet in small regional cohorts such as Japan's 8% representation in ARCHES, wide intervals often reflect limited precision rather than biological heterogeneity. Bayesian analysis, in contrast, explicitly quantifies uncertainty as a probability distribution, allowing integration of prior evidence and more nuanced communication of treatment benefit. In this reanalysis, even under a neutral prior, the posterior probability of benefit exceeded 90%, illustrating that apparent “non-significance” does not equate to “no effect.” Beyond its statistical sophistication, this study raises a conceptual point about equity in global drug development. Multiregional clinical trials increasingly include small East Asian cohorts primarily to satisfy regulatory expectations, yet conclusions drawn from underpowered subgroup analyses can influence national access decisions. Bayesian borrowing of strength from global data may help contextualize these results, provided transparency about the priors and their dependence on shared information. Yajima et al. acknowledge this limitation candidly—the unavoidable “double counting” of Japanese patients within the global prior—and appropriately present their analysis as didactic rather than confirmatory. From an educational perspective, the authors succeed in illustrating how prior choice governs posterior inference. Their tiered sensitivity analysis (neutral, conservative, moderate, and strong borrowing) demonstrates that with informative priors, credible intervals quickly converge toward the global estimate (HR ≈ 0.39). This outcome is mathematically inevitable given the large disparity in sample sizes (1150 vs. 92), yet it provides a valuable teaching example for clinicians seeking to understand why Bayesian posterior means can appear deceptively precise. Importantly, their discussion avoids overstating conclusions; the work is presented not as new clinical evidence but as an invitation to rethink how uncertainty is conveyed to patients and policymakers. Future multinational trials could benefit from pre-specifying Bayesian supplementary analyses for key regional subgroups, ideally using independent historical data or registry information to construct priors. Such approaches may improve interpretability when recruitment challenges preclude adequately powered local samples. Moreover, presenting probabilities such as P (HR < 1) or P (HR < 0.8) alongside conventional hazard ratios could enhance communication with clinicians and regulators alike, bridging the gap between statistical inference and practical decision-making. In summary, this Bayesian reanalysis does not alter the clinical message of ARCHES—that enzalutamide plus ADT remains effective across populations—but it enriches our understanding of how evidence can be expressed. By translating abstract uncertainty into tangible probability, Yajima et al. remind us that the absence of statistical significance should never be mistaken for the absence of therapeutic benefit. The author takes full responsibility for this article. The author declares no conflicts of interest. This article is linked to https://doi.org/10.1111/iju.70256.